Tsuboi, MasahiroMasahiroTsuboiGoldman, Jonathan WJonathan WGoldmanWu, Yi-LongYi-LongWuJohnson, Melissa LMelissa LJohnsonPaz-Ares, LuisLuisPaz-AresCHIH-HSIN YANGBesse, BenjaminBenjaminBesseSu, WeijiWeijiSuChao, Bo HBo HChaoDrilon, AlexanderAlexanderDrilon2023-03-022023-03-022022-091479-6694https://scholars.lib.ntu.edu.tw/handle/123456789/628837Selpercatinib, a first-in-class, highly selective and potent central nervous system-active RET kinase inhibitor demonstrated clinically meaningful activity with manageable toxicity in pretreated and treatment-naive advanced/metastatic RET fusion-positive non-small-cell lung cancer (NSCLC). LIBRETTO-432 is a global, randomized, double-blind, phase III trial evaluating selpercatinib versus placebo in stage IB-IIIA, RET fusion-positive NSCLC, previously treated with definitive surgery or radiation; participants must have undergone available anti-cancer therapy (including chemotherapy or durvalumab) or not be suitable for it, per investigator's discretion. The primary end point is investigator-assessed event-free survival (EFS) in the primary analysis population (stage II-IIIA RET fusion-positive NSCLC). Key secondary end points include EFS in the overall population, overall survival, and time to distant disease recurrence in the central nervous system.enRET fusion-positive; RET kinase inhibitor; RET rearrangement; adjuvant therapy; early stage; non-small-cell lung cancer; phase III trial; selpercatinib; stage IB; stage II; stage IIIA; targeted therapy[SDGs]SDG3review10.2217/fon-2022-0656359505662-s2.0-85139880560WOS:000838720700001https://api.elsevier.com/content/abstract/scopus_id/85139880560